{"url_path":"/sec/armp/8-k/2026-07-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-084860-index.html","accession_number":"0001104659-26-084860","cik":"0000921114","ticker":"ARMP","issuer_name":"Armata Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-084860-index.html","primary_entity_key":"0000921114","primary_entity_name":"Armata Pharmaceuticals, Inc."},"word_count":123,"has_tables":true,"body_markdown":"**Item 9.01.****Financial Statements and Exhibits.**\n\n \n\n**(d)       Exhibits**\n\n \n\n[10.1](tm2620782d1_ex10-1.htm)\n[Employment Letter Agreement, dated July 17, 2026, by and between Armata Pharmaceuticals, Inc. and David House.](tm2620782d1_ex10-1.htm)\n\n \n \n\n[10.2](tm2620782d1_ex10-2.htm)\n[Amendment No. 1, dated July 17, 2026, to that certain Employment Letter Agreement, dated June 1, 2024, by and between Armata Pharmaceuticals, Inc. and Pierre Kyme.](tm2620782d1_ex10-2.htm)\n\n \n \n\n104\nCover Page Interactive Data File (embedded within Inline XBRL document)\n\n \n\n- 3 -\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\nDate: July 18, 2026\nArmata Pharmaceuticals, Inc.\n\n \n \n\n \nBy:\n/s/ Deborah L. Birx\n\n \nName: \nDeborah L. Birx, M.D.\n\n \nTitle: \nChief Executive Officer\n\n \n \n(Principal Executive Officer)\n\n \n\n- 4 -"}